期刊文献+

硼替佐米为基础的化疗方案治疗多发性骨髓瘤患者的疗效及预后因素分析 被引量:33

Bortezomib-based chemotherapy for patients with multiple myeloma: a single center experience
分享 导出
摘要 目的研究硼替佐米为主的化疗方案治疗多发性骨髓瘤患者的临床疗效及安全性。方法80例患者采用硼替佐米联合地塞米松或硼替佐米联合地塞米松及阿霉素方案化疗。其中16例患者化疗后联合自体或异基因造血干细胞移植巩固治疗。评价其疗效及不良反应,并进行生存分析。结果80例患者中位年龄57(25~78)岁,总反应率80%,完全缓解(CR)率46.3%。中位随访25(1-81)个月,患者1年及2年总生存(OS)率分别为81.4%和72.9%,1年及2年无进展生存(PrS)率分别为76.0%和62.5%。其中16例患者化疗后序贯造血干细胞移植治疗,序贯移植组及单纯化疗组患者2年OS率分别为100.0%和66.0%(P=0.029),2年PFS率分别为73.9%和58.7%(P=0.447)。单因素分析中,影响OS的因素包括Durie—Salmon分期(肾功能是否异常)(P=0.010)、国际分期系统分期(P=0.009)、用药后是否达CR及非常好的部分缓解(VGPR)(P=0.002)、是否序贯造血干细胞移植(P=0.029);影响PFS的因素包括性别(P=0.026)及是否存在髓外病变(P=0.025)。多因素分析中,延长OS的因素为最佳疗效达CR及VGPR(P=0.001)、Durie—Salmon分期A组(无肾功能异常)(P=0.006)及序贯造血干细胞移植治疗(P=0.052);延长PFS的因素为男性(P=0.020)及不伴髓外病变(P=0.030)。结论硼替佐米为主的化疗可有效地治疗初治及难治复发的多发性骨髓瘤患者,联合自体或异基因造血干细胞移植可以进一步提高患者0S率。 Objective To evaluate the efficacy and safety of bortezomib-based chemotherapy for 80 patients with multiple myeloma (MM). Methods A total of 80 cases with a median age of 57 (range: 25-78) years were enrolled in the study. Bortezomib-based regimens included VD (bortezomib and dexamethasone) and PAD (bortezomib, doxombicin and dexamethasone). 16 of the 80 patients received autologous or allo-hematopoietic stem cell transplantation (HSCT). Results The overall response (OR) rate was 80%, including a complete response (CR) of 46.3%. After a median follow-up of 25 months, the 1-year and 2-year overall survival (OS) was 81.4% and 72.9%, and the 2-year progression-free survival (PFS) was 76% and 62.5%, respectively. The 2-year OS and PFS were 100% and 73.9 % in patients with HSCT, while both were 66% (P=-0.029) and 58.7% (P=0.447) in patients without HSCT. In univariate analysis, Dnrie-Salmon group, ISS stage, CR and very good partial response (VGPR), and HSCT were prognostic factors for OS. Gender and extramedullary plasmacytomas were important prognostic factors for PFS. Multivariate analysis by Cox regression revealed that CR and VGPR, Dnrie-Salmon group A, and HSCT were prognostic factors for better OS; while male and patients without extramedullary plasmacytomas were prognostic factors for longer PFS. Conclusion MM patients could benefit from bortezomib-based chemotherapy with satisfactory efficacy and safety. HSCT could improve the OS for young MM patients.
作者 梁赜隐 任汉云 岑溪南 李渊 王莉红 欧晋平 董玉君 尹玥 王文生 刘微 王倩 邱志祥 王茫桔 许蔚林 孙玉华 Liang Zeyin, Ren Hanyun, Cen Xinan, Li Yuan, Wang Lihong, Ou Jinping, Dong Yujun, Hn Yue, Wang Wensheng, Liu Wei, Wang Qian, Qiu Zhixiang, Wang Man,u, Xu Weilin, Sun Yuhua. Department of Hematology, Peking University First Hospital, Beijing 100034, China
出处 《中华血液学杂志》 CAS CSCD 北大核心 2014年第3期225-230,共6页 Chinese Journal of Hematology
基金 卫生公益性行业科研专项(2012020217)
关键词 多发性骨髓瘤 硼替佐米 造血干细胞移植 存活率分析 Multiple myeloma Bortezomib Hematopoietic stem cell transplantation Survival analysis
作者简介 通信作者:任汉云,Email:renhy0813@163.com
  • 相关文献

参考文献18

  • 1Kastritis E, Zervas K, Symeonidis A, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG) [J]. Leukemia, 2009, 23(6):1152-1157. 被引量:1
  • 2Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem- cell transplantation in newly diagnosed multiple myeloma: re- suits of the IFM 2005-01 phase III trial [J]. J Clin Oncol, 2010, 28(30): 4621-4629. 被引量:1
  • 3Rosifiol L, Oriol A, Ternel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretrans- plantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study [J]. Blood, 2012, 120(8): 1589-1596. 被引量:1
  • 4Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study [Jl. Lancet, 2010, 376 (9758): 2075-2085. 被引量:1
  • 5Harousseau JL, Palumbo A, Richardson PG, et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone [J]. Blood, 2010, 116(19): 3743-3750. 被引量:1
  • 6Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma IJ]. Leukemia, 2009, 23 ( 1 ):3-9. 被引量:1
  • 7Greipp PR, San Miguel J, Durie BG, et al. International stagingsystem for multiple myeloma [J]. J Clin Oncol, 2005, 23 (15): 3412-3420. 被引量:1
  • 8Piro E, Molica S. A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence? [J]. Acta Haemat, 2011, 126(3):163-168. 被引量:1
  • 9Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications IJl. Blood, 2003, 101 (6):2377-2380. 被引量:1
  • 10陈晨,赵川莉,侯明,王鲁群,刘传方,宋强,纪春岩.硼替佐米为主方案治疗多发性骨髓瘤患者的临床研究[J].中华血液学杂志,2011,32(4):265-267. 被引量:11

二级参考文献8

  • 1Palumbo A,Bringhen S,Caravita T,et al.Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma:randomised controlled trial.Lancet,2006,367:825-831. 被引量:1
  • 2National Comprehensive Cancer Network (NCCN).NCCN Clinical Practice Guidelines in Oncology MM (2009 V3).http://www.nccn.org. 被引量:1
  • 3Oakervee HE,Popat R,Curry N,et al.PAD combination therapy (PS-341/bortezomib,doxorbicin and dexamethasone) for previously untreated patients with multiple myeloma.Br J Haematol,2005,129:755-762. 被引量:1
  • 4Richardson PG,Barlogie B,Berenson J,et al.Extended follow-up of a phase Ⅱ trial in relapsed,refractory multiple myeloma:final time-to-event results from the SUMMIT trial.Cancer,2006,106:1316-1319. 被引量:1
  • 5Bladé J,Samson D,Reece D,et al.Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem cell transplantation.Myeloma Committee of the EBMT European Group for Blood and Marrow Transplant.Br J Haematol,1998,102:1115-1231. 被引量:1
  • 6Anderson KC.Multiple myeloma:how far have we come? Mayo Clin Proc,2003,78:15-17. 被引量:1
  • 7Manochakian R,Miller KC,Chanan-Khan AA.Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma.Oncologist,2007,12:978-990. 被引量:1
  • 8Lee SJ,Richardson PG,Sonneveld P,et al.Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma:results from the APEX study.Br J Haematol,2008,143:511-519. 被引量:1

共引文献10

同被引文献210

引证文献33

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈